RT @drdavidliew: @EricFMorand up first in late-breakings PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid
Tweet Content
@EricFMorand up first in late-breakings
PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean
Good outcomes:
primary: SRI(4) at 32w
skin/joint/LLDAS & dsDNA/C4
Safety good (like PsO/PsA) but higher dose less so
Watch for: other clinical, ph3
#EULAR2022 @RheumNow https://t.co/XOQWuiHkTx
Show on Archive Page
On
Display in Search Results
On
PDQ
Off